5 big pharma companies agree to decarbonise operations in China
Following extensive talks, leading pharmaceutical companies sign an agreement to work with renewable energy companies to decarbonise their manufacturing supply chains in China and switch to renewables.
Renewable energy in pharmaceuticals is considered one of the most important areas to tackle in terms of climate change, and an aspect that pharmaceutical companies have the means and room to improve.
Making a statement move in this direction are five of the biggest global pharmaceutical and healthcare companies: AstraZeneca, Lonza, Novartis, Novo Nordisk, and Roche, who have all signed a renewable power agreement in China. The agreement is an industry first, with such big players setting the bar by agreeing to decarbonise their operations in China.
The companies, four of whom are already members of the Sustainable Markets Initiative Health Systems Task Force, announced their agreement, which is to last at least 3 years, at the World Economic Forum in Davos, Switzerland. The plan sets out to support China on its path to becoming carbon neutral, and aims to unlock 200 GWh of renewable electricity annually from 2024 across Jiangsu, Guangdong, Shanghai, and Beijing. The resulting reduction in emissions will amount to 120,000 tonnes of carbon dioxide equivalent (CO2e).
The agreement comes after talks between the companies preceding COP28, where healthcare and pharma were broadly considered within sustainability initiatives and plans, more so than ever before. This latest agreement also lays the groundwork for other companies, with the option to join the initiative to work together to decarbonise their supply chains in China. Manufacturing supply chains are responsible for more than half of the emissions produced from the pharmaceutical sector, so changing to renewable energy will cut these considerably across the industry.
To facilitate the switch to renewable energy Envision Energy, one of the biggest renewable energy firms in China, will be providing the electricity. The majority of the participating companies are involved in several other sustainability initiatives, and from this have developed further connections to a working group in China involving 16 Chinese companies spanning health, energy, and digital, to reduce the global impact China’s energy consumption has.
The Sustainable Markets Initiative’s Health Systems Task Force continues to work with and encourage further partnerships to deliver more sustainable frameworks and tackle climate change throughout the sector.
Related News
-
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News CPHI Podcast Series: analysing supplier audits with the PSCI
This episode of the CPHI Podcast Series, hosted by Digital Editor Lucy Chard, goes through the results from the recent audits from the PSCI conducted on suppliers across the pharmaceutical industry, looking into ESG outcomes. -
News CPHI Online Trend Report: what is pharmaceutical packaging really costing the industry?
The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy. -
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Press release: CPHI Sustainability Report 2024 – a guide to a greener industry
The CPHI Pharma portfolio is pleased to announce that their annual Sustainability Report has been published, with thought leaders outlining a guide to a greener pharmaceutical industry. -
News The PSCI publishes Materiality Assessment of the Pharma Supply Chain
In the latest instalment of the PSCI blog on CPHI Online, The PSCI introduces the 2024 PSCI Supply Chain Materiality Assessment, the first public materialty assessment of the pharmaceutical supply chain they have worked on. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News On Track at CPHI NA 2024: Sustainable Futures with Thermo Fisher Scientific
On the 7-9 May 2024 in Philadelphia, CPHI NA will be presenting an unmissable agenda, filled with content across 4 main tracks. In the following interview the Sustainable Futures Track sponsor, Thermo Fisher Scientific gives an overview of what to expe...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance